Cargando…
Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and pro...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502559/ https://www.ncbi.nlm.nih.gov/pubmed/23057417 http://dx.doi.org/10.1186/1471-230X-12-139 |
_version_ | 1782250367181914112 |
---|---|
author | Yamasaki, Kazumi Tomohiro, Mayumi Nagao, Yumiko Sata, Michio Shimoda, Toshiaki Hirase, Kazuhiro Shirahama, Satoshi |
author_facet | Yamasaki, Kazumi Tomohiro, Mayumi Nagao, Yumiko Sata, Michio Shimoda, Toshiaki Hirase, Kazuhiro Shirahama, Satoshi |
author_sort | Yamasaki, Kazumi |
collection | PubMed |
description | BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and prospectively investigate the effects of IFN treatment in comparison with the HCV-negative general population. METHODS: HCV antibody was positive in 1,343 (7.6%) of the 17,712 individuals screened. 792 HCV RNA-positive, HBsAg-negative subjects were enrolled. 1,584 HCV antibody-negative, HBsAg-negative general residents were sex- and age-matched to the 792 subjects. A total of 154 <70-year-old patients without liver cirrhosis (LC) or hepatocellular carcinoma (HCC) underwent IFN treatment. The survival rate with all-cause death as the endpoint was determined and causes of death were compared. RESULTS: The 10- and 20-year survival rates of the hepatitis C and general resident groups were 65.4% and 87.8%, and 40.8% and 62.5%, respectively (p < 0.001; hazard risk ratio, 0.444; 95% confidence interval (CI): 0.389–0.507). There were 167 liver disease-related deaths and 223 deaths from other causes in the hepatitis C group, and 7 and 451, respectively, in the general resident group. Liver disease-related death accounted for 43.8% and 1.5% of deaths in the hepatitis C and general resident groups (p < 0.0001). The cumulative survival rate of the hepatitis C patients without IFN (n = 328) was significantly lower than the gender- and age-matched general resident group (n = 656) (p < 0.0001) but there was no significant difference between the IFN-treated (n = 154) and general resident groups (n = 308). CONCLUSIONS: In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the survival rate lower, than the general resident group. Introduction of IFN treatment in <70-year-old patients with hepatitis C without LC or HCC improved the survival rate to a level comparable to that of the general residents. |
format | Online Article Text |
id | pubmed-3502559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35025592012-11-22 Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients Yamasaki, Kazumi Tomohiro, Mayumi Nagao, Yumiko Sata, Michio Shimoda, Toshiaki Hirase, Kazuhiro Shirahama, Satoshi BMC Gastroenterol Research Article BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and prospectively investigate the effects of IFN treatment in comparison with the HCV-negative general population. METHODS: HCV antibody was positive in 1,343 (7.6%) of the 17,712 individuals screened. 792 HCV RNA-positive, HBsAg-negative subjects were enrolled. 1,584 HCV antibody-negative, HBsAg-negative general residents were sex- and age-matched to the 792 subjects. A total of 154 <70-year-old patients without liver cirrhosis (LC) or hepatocellular carcinoma (HCC) underwent IFN treatment. The survival rate with all-cause death as the endpoint was determined and causes of death were compared. RESULTS: The 10- and 20-year survival rates of the hepatitis C and general resident groups were 65.4% and 87.8%, and 40.8% and 62.5%, respectively (p < 0.001; hazard risk ratio, 0.444; 95% confidence interval (CI): 0.389–0.507). There were 167 liver disease-related deaths and 223 deaths from other causes in the hepatitis C group, and 7 and 451, respectively, in the general resident group. Liver disease-related death accounted for 43.8% and 1.5% of deaths in the hepatitis C and general resident groups (p < 0.0001). The cumulative survival rate of the hepatitis C patients without IFN (n = 328) was significantly lower than the gender- and age-matched general resident group (n = 656) (p < 0.0001) but there was no significant difference between the IFN-treated (n = 154) and general resident groups (n = 308). CONCLUSIONS: In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the survival rate lower, than the general resident group. Introduction of IFN treatment in <70-year-old patients with hepatitis C without LC or HCC improved the survival rate to a level comparable to that of the general residents. BioMed Central 2012-10-12 /pmc/articles/PMC3502559/ /pubmed/23057417 http://dx.doi.org/10.1186/1471-230X-12-139 Text en Copyright ©2012 Yamasaki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Yamasaki, Kazumi Tomohiro, Mayumi Nagao, Yumiko Sata, Michio Shimoda, Toshiaki Hirase, Kazuhiro Shirahama, Satoshi Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title | Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title_full | Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title_fullStr | Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title_full_unstemmed | Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title_short | Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients |
title_sort | effects and outcomes of interferon treatment in japanese hepatitis c patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502559/ https://www.ncbi.nlm.nih.gov/pubmed/23057417 http://dx.doi.org/10.1186/1471-230X-12-139 |
work_keys_str_mv | AT yamasakikazumi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT tomohiromayumi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT nagaoyumiko effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT satamichio effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT shimodatoshiaki effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT hirasekazuhiro effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients AT shirahamasatoshi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients |